REGISTER
ATS Chair: What Stood Out at This Year's Conference
At ATS 2026, AI integration and late-breaking clinical trials took center stage, with emerging oral and inhaled therapies for PAH, sleep apnea, and ILD signaling a shift from symptom management toward disease modification.

Raed A. Dweik, MD, President, American Thoracic Society | Professor of Medicine, Cleveland Clinic Lerner College of Medicine, USA

ATS 2025 brought two converging themes to the fore: the rapid integration of artificial intelligence into respiratory medicine, and a wave of late-breaking clinical trials. New oral and inhaled therapies for pulmonary arterial hypertension, sleep apnea, and interstitial lung disease are moving the field from symptom management toward disease modification. Dr. Dweik highlights the sessions and resources he recommends most for clinicians who could not attend in person.

0
0
Loading